AstraZeneca is trading at £13,446.00, up 3.02%, after Q3 revenue and adjusted EPS both beat analyst expectations.
- Q3 revenue was $16.21 billion and adjusted EPS was $2.79. Strong cancer-drug sales helped drive the results.
- Management reiterated 2026 guidance, announced a restructuring programme targeting about $1.5 billion in annual savings, and raised its 2026 dividend to $3.30 per share.